Aardvark Therapeutics' stock dropped 32% following the FDA's decision to place a full clinical hold on its lead drug candidate ARD-101, used to treat Prader-Willi Syndrome. This follows a prior 56% drop in March when the company paused its Phase 3 trial due to serious safety concerns involving cardiac issues. The clinical hold affects all ongoing studies under the drug's IND application, raising questions about the drug's safety and efficacy claims. A shareholder rights firm is investigating whether Aardvark misled investors about these issues, and investors with losses are encouraged to come forward.
YieldMax ETFs announced weekly distributions for their Group 1 ETFs, with distribution rates ranging from 26.17% to 60.34% annualized. These ETFs cover sectors like semiconductors, AI & tech, crypto, metals, and covered call strategies. Distributions...
The global ultrasonic aspirator market, valued at $194 million in 2025, is projected to grow at a CAGR of 6.87% to reach $376 million by 2035. Growth is fueled by increased use in neurosurgery, orthopedic, and minimally invasive surgeries, driven by ...
MEXC's RealStocks platform, launched in June 2026, saw SpaceX (SPCX) capture nearly 30% of trading volume and user activity, marking it as the most popular stock among over 7,000 US stocks and ETFs available. AI-related stocks collectively accounted ...
The SCHD ETF currently offers a 3.3% yield and is on track to complete its 15th consecutive year of dividend increases in 2026. This consistent dividend growth highlights SCHD's appeal for income-focused investors seeking reliable payouts. Maintainin...
Dimensional Fund Advisors Ltd. has publicly disclosed holding a 1.26% ownership stake in Prologis Inc, totaling 11,789,090 shares as of July 27, 2026. This disclosure is made under Rule 8.3 of the Takeover Code, indicating a significant investment po...
